Department of Neurosurgery, Nanfang Hospital, Southern Medical University, No. 1838, North Guangzhou Avenue, 510515, Guangzhou, Guangdong, People's Republic of China.
Nanfang Glioma Center, Nanfang Hospital, Southern Medical University, 510515, Guangzhou, Guangdong, People's Republic of China.
Mol Biotechnol. 2024 Sep;66(9):2308-2321. doi: 10.1007/s12033-023-00820-0. Epub 2023 Aug 29.
Gliomas is a deadly disease without effective therapy. Although immunotherapy has provided novel choices for glioma treatment, the curative efficacy is unsatisfactory due to the complex immune micro-environment and the heterogeneity of the disease. Therefore, it is urgent to identify effective biomarkers and therapeutic targets.
Overall survival, gene ontology (GO), Kyoto Encyclopedia of Genes, and Genomes (KEGG) enrichment analysis, Gene Set Enrichment Analysis (GSEA) and immune infiltration were analyzed by bioinformatics software with The Cancer Genome Atlas (TCGA) database.
Based on the TCGA database and protein-protein interaction (PPI) analysis revealed a four-gene panels [DNA topoisomerase II alpha (TOP2A); ribonucleotide reductase regulatory subunit M2 (RRM2); kinesin family member 20 A (KIF20A) and DLG associated protein 5 (DLGAP5)], which correlated with poor prognosis, including overall survival (OS), disease specific survival (DSS) and progress free interval (PFI), mitosis, cell cycle, Th2 cells and macrophages enrichment. The four-gene panels correlates with the biomarkers of Th2 cells, macrophages tumor-associated macrophages (TAMs) and the immune checkpoint molecules in gliomas.
The four-gene panels represented a novel prognostic indicator and potential therapeutic target for the treatment of glioma. In addition, the four-gene panels might contribute to enhance the efficacy of immunotherapy in glioma.
神经胶质瘤是一种致命的疾病，目前尚无有效的治疗方法。尽管免疫疗法为神经胶质瘤的治疗提供了新的选择，但由于复杂的免疫微环境和疾病的异质性，疗效并不理想。因此，迫切需要识别有效的生物标志物和治疗靶点。
利用生物信息学软件对癌症基因组图谱（TCGA）数据库进行总生存期、基因本体（GO）、京都基因与基因组百科全书（KEGG）富集分析、基因集富集分析（GSEA）和免疫浸润分析。
基于 TCGA 数据库和蛋白质-蛋白质相互作用（PPI）分析，揭示了一个由四个基因组成的基因面板[拓扑异构酶 IIα（TOP2A）；核糖核苷酸还原酶调节亚基 M2（RRM2）；驱动蛋白家族成员 20A（KIF20A）和Dlg 相关蛋白 5（DLGAP5）]，与不良预后相关，包括总生存期（OS）、疾病特异性生存期（DSS）和无进展生存期（PFI）、有丝分裂、细胞周期、Th2 细胞和巨噬细胞富集。该四个基因面板与神经胶质瘤中 Th2 细胞、巨噬细胞肿瘤相关巨噬细胞（TAMs）和免疫检查点分子的生物标志物相关。
该四个基因面板代表了神经胶质瘤治疗的一种新的预后指标和潜在的治疗靶点。此外，该四个基因面板可能有助于提高神经胶质瘤免疫治疗的疗效。
